Wednesday, July 8, 2026

pharma · Diabetes Mellitus, Type 2 · Sickle Cell Disease · CYCN

Cyclerion Therapeutics

Cyclo Therapeutics is a pharma organization headquartered in Gainesville, USA. It trades on NYSE under ticker CYCN. Primary therapeutic focus areas include Diabetes Mellitus, Type 2, Sickle Cell Disease, Achalasia. NovaP

Gainesville, USA HQ
1990 Founded
14 Employees
Public company Type
CYCN · NYSE Ticker
Company details
Status
Public
HQ
Gainesville, USA
Founded
1990
Employees
14
Programs
9
Drugs
2
Patents
17
Clinical program

Matching Placebo

Phase 2 · small molecule · Diabetes Mellitus, Type 2

Matching Placebo for Diabetes Mellitus, Type 2 is a Phase 2 program (small_molecule) at Cyclerion Therapeutics with 1 ClinicalTrials.gov record(s).

← All Cyclerion Therapeutics projects Phase 2 small molecule completed

Internal code C1973-201

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Cyclerion Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Diabetes Mellitus, Type 2
Status
completed
Trials
1